Last edition
News about "RSV glycoprotein F antigen"
European Commission Expands GSK's RSV Vaccine Arexvy to Adults Aged 18 and Above
GSK’s RSV vaccine Arexvy receives European approval for adults aged 18 plus, marking a major expansion in protection against RSV-related respiratory illness across the region.
RSV Glycoprotein F Antigen | 28/01/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members